Long-Term Safety and Tolerability of BHV-7000 in MDD

Phase 2, open-label, single-arm trial of opakalim in major depressive disorder (MDD), sponsored by Biohaven Ltd. Primary endpoints: Number of Participants With Serious AEs (SAEs), AEs Leading to Study Drug Discontinuation, and AEs judged to be related to study medication at 104 weeks, Number of Participants With Clinically Significant Laboratory Abnormalities at 104 weeks and 2 more. Started Aug 2024; status: completed.